In this episode of Prostate Cancer and You, host Jordan Rich speaks with Dr. Todd Cohen of Blue Earth Diagnostics about the growing role of radioligand therapy in prostate cancer treatment.

Dr. Cohen explains how PSMA-targeted imaging and radioligand therapy work together to identify and treat prostate cancer with greater precision. The discussion covers which patients may be candidates for these therapies, how treatment decisions are made, and what emerging research may mean for future care.

Dr. Todd Cohen earned his MD from the University of Rochester and completed a Urology residency at the Cleveland Clinic, followed by a fellowship at Duke. He founded Piedmont Urology in Charlotte, NC, and co-founded Carolina Urology Partners, serving as CEO for nine years. He held leadership roles at Myriad Genetics and currently serves as VP of Medical Affairs at Blue Earth Diagnostics.